7 results
The primary objective of this study is to evaluate the effects of a CYP2D6 inhibitor, paroxetine, on the pharmacokinetics of a single dose of orally administered paliperidone ER. The safety and tolerability of the 3 mg tablet of paliperidone ER…
Primary Objective: The main objective is to compare the effectiveness and cost-effectiveness of Cognitive Behavioural Therapy (CBT) to psychopharmacological treatment with paroxetine in patients with Posttraumatic stress disorder (PTSD) in a…
Primary objective:To show that concomitant use of telaprevir (1125 mg BID) does not lead to a relevant decrease (> 20%) in the paroxetine parameter AUC0-24h compared to paroxetine alone.Secondary objectives:To determine the ratio of the…
See protocol page 23This study is designed to assess the usability and functionality of the Reveal LINQ system. Data from the first 30 patients, with 30 days of follow-up, will be used to assess sensing performance and wireless capabilities of the…
Inhibition of CYP2D6 enzymes by SSRIs may lead to reduced endoxifen plasma concentrations and thereby possibly influence tamoxifen treatment outcome. Paroxetine is a potent CYP2D6 inhibitor and strongly reduces endoxifen plasma concentrations.…
To investigate the feasibility of a newly proposed method with the non-invasive Optimedic dynamic neuromodulator for chronic low back pain patients. Stakeholders will be interviewed to objectify the feasibility of the methods used in this study.A…
TEMPO will directly compare i) conventional 2-step reduction with ii) gradual tapering in patients with remitted MDD who use either the antidepressant paroxetine (PAR) or venlafaxine (VLX). We will evaluate the number of patients that can…